An article published in the Journal of the American Medical Association (JAMA) reveals that some fibroids can be helped by the new treatment of a medication dubbed FCPMs.
Researchers at the University of North Carolina at Chapel Hill studied the effectiveness of FCPMS in patients with fibromyarthritis, and found that it significantly improved their quality of life.
This was the first time a drug has been used to treat fibromyroids, and researchers said that they believe the drug may be able to help with other ailments as well.
“The FCPs were effective for reducing pain, and we were able to see that for a variety of patients,” said senior author James J. Brown, MD, PhD, associate professor of medicine at the UNC School of Medicine.
“Some people who had chronic pain in their life, or had a chronic disease, and were getting very poorly treated by a lot of medications, they were finding that they could get relief from the FCP medication, which helped them to get better,” Brown said.FCPMs are an alternative to the traditional drugs commonly used to relieve symptoms of fibromyromyalgia.
They’re not approved by the Food and Drug Administration and can cost up to $1,000 a month, but patients have reported being able to get relief with FCPMDs.
Patients who have had their condition for more than six months are also able to receive FCPMHs.
The drug was originally developed in the 1990s, but research on FCPMOs has since improved, according to the researchers.
Patients have reported improvement in their quality and pain levels.
The study also showed that FCPMM had a significant impact on other aspects of patients’ lives.
The researchers say that FCEPs are the most effective type of treatment for fibromyarthritis, and the medication is also effective for other other conditions such as fibromyal parkinsonism, irritable bowel syndrome, and arthritis.
Brown says that this research suggests that FCTM may be useful for other conditions as well, and that the drug could potentially be used for other problems as well as fibrocystic arthritis.
“I would hope that we would find that FCHM could be used in other conditions, like other conditions associated with inflammatory bowel disease, which could be another avenue that could lead to new treatments for other diseases,” he said.
The research was funded by the National Institutes of Health.